

HASAN AND SINGH

Intellectuals @ Law

Advocates, Patent And Trademark Attorneys

Newsletter March 2015

1. Centre approves 25 panels of experts for SECs for evaluation of applications of clinical trials, new drugs & devices.

The Union health ministry has approved 25 panels of experts of various therapeutic areas for evaluation of various categories of applications of clinical trials, new drugs and new medical devices. These SECs will advise the DCGI for the in-depth evaluation of non-clinical data including pharmacological toxicological data, clinical trial data (phase I, II, III, and IV) etc. furnished by the applicants for approval of new drug substance of chemical and biological origin and new medical device to be introduced for the first time in the country including vaccines & r-DNA derived products.

[Read More..](#)

2. Indian scientists turn coconut oil into biofuel.

Scientists who have been running the four-stroke diesel engine of a light pick-up truck on coconut oil for the past one year have approached the union government to

commercialise the biofuel.

[Read More..](#)

3. Delhi HC allows Glenmark to make, sell antibiotic drug Linezolid.

Delhi High Court on 5th February set aside its single judge's order restraining Mumbai-based generic drug maker Glenmark Pharmaceuticals Ltd from making and selling its antibiotic medicine Linezolid. Linezolid is a synthetic antibiotic used to treat infections of the skin and blood, as also pneumonia. A bench of justices Badar Durrez Ahmed and Sanjeev Sachdeva, while setting aside the single judge's 19 January interim order, directed Glenmark to maintain accounts of manufacture and sale of its medicine and file the same in the court.

[Read More..](#)

4. Microsoft and Samsung make up in patent contract dispute.

Microsoft and Samsung Electronics have settled a dispute over payment of royalties to the software giant. The agreements between the

two companies also provided for credits and potential reimbursements for marketing expenses to Samsung for the development of smartphones and tablets running the Windows operating system from Microsoft.

[Read More..](#)

5. US and Japan join the Hague System.

The US and Japan are the latest countries to join the Hague System for the International Registration of Industrial Designs, meaning the number of countries covered by the agreement now totals 64. Their entering into the agreement will mean that industrial design applicants in both the US and Japan will be able to file just a single application to cover all the nations signed up to the agreement, rather than separate ones in multiple jurisdictions. Designers in other Hague countries will also have easier access to the US and Japan.

[Read More..](#)

6. NPPA rolls back proposal on display of distinguishing mark & ceiling prices of

HASAN AND SINGH

Intellectuals @ Law

Advocates, Patent And Trademark Attorneys

scheduled drugs on labels.

The National Pharmaceutical Pricing Authority (NPPA) has rolled back its earlier proposal for display of distinguishing mark and ceiling prices of scheduled drugs on the label of the drugs, to make consumers aware about the ceiling prices of controlled drugs as notified by the NPPA from time to time.

[Read More..](#)

7. BHU researchers develop biosensor to predict heart attack.

Researchers from the department of biochemistry, Institute of Medical Sciences, Banaras Hindu University (BHU) have made a sensitive and specific graphene oxide-based electrochemical biosensor for detection of specific micro-particles in blood samples and predict the risk of heart attack or brain stroke. IMS has already applied for its patenting.

[Read More..](#)

8. Microsoft, ZTE do not infringe InterDigital patents: Court.

InterDigital, a patent licensing

firm, lost an infringement fight on 18th February as a US appeals court ruled that wireless phones made by Nokia, since purchased by Microsoft, and ZTE do not infringe on InterDigital patents. The US Court of Appeals for the Federal Circuit upheld a decision by the International Trade Commission, which found the patents were not infringed.

[Read More..](#)

9. Mylan to Distribute Gilead's Hepatitis C Drugs in India.

Mylan Inc. Indian subsidiary will be the exclusive distributor of Gilead Sciences Inc hepatitis C treatments. Under the deal, Mylan will distribute Gilead's Sovaldi and Harvoni hepatitis C treatments, starting in the second quarter. Mylan will also have nonexclusive rights to manufacture and distribute generic versions of Sovaldi, Harvoni and—upon approval—two investigational hepatitis C treatments in 91 developing countries.

[Read More..](#)

10. Merck grants free

license for pediatric HIV drug.

Drugmaker Merck & Co. has granted a free license allowing one of its HIV medicines to be made and sold inexpensively for use in young children in poor countries hard hit by the AIDS virus.

[Read More..](#)

11. Apple ordered to pay \$533 million for patent infringement

Apple Inc has been ordered to pay \$532.9 million after a federal jury in Texas found that its iTunes software infringed three patents owned by patent licensing firm Smartflash LLC.

[Read More..](#)

12. No proposal to change patent law.

Indian government ruled out amendment to the patent law, asserting that there are no gaps in protection of Intellectual Property Rights (IPR).

[Read More..](#)